Skip to main content

Table 2 Patient characteristics

From: Hospitalisation costs of metastatic melanoma in France; the MELISSA study (MELanoma In hoSpital coSts Assessment)

 

Pre-progression(N = 7332)

Post-progression(N = 5062)

Total(N = 8862)

Gender

 Men

3894 (53.1%)

2829 (55.9%)

4764 (53.8%)

 Women

3438 (46.9%)

2233 (44.1%)

4098 (46.2%)

Age (years)

 Mean ± SD

63.4 ± 15.9

64.2 ± 15.7

63.7 ± 15.9

 Median (Min. – Max.)

65 (18–103)

66 (18–99)

65 (18–103)

Initial progression marker

 Cerebral metastasesa

 

1348 (26.6%)

 

 New metastases in other sites

 

2027 (40.0%)

 

 Palliative care

 

1058 (20.9%)

 

  With cerebral metastases

 

300 (5.9%)

 

  Without cerebral metastases

 

758 (15.0%)

 

 Treatment change

 

629 (12.4%)

 
  1. aWithout delivery of palliative care